Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xiapex for Refractory Iatrogenic Esophageal Strictures
NCT03898661Phase 1Terminated
- Sponsor
- Ghent University Hospital
- Start
- Mar 2019
- Primary completion
- Jun 2020
- Modality
- Therapeutic Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of collagenase clostridium histolyticum in Esophageal stricture (2 arms), sponsored by Ghent University Hospital. Primary endpoint: Number of repeat dilations that are required over a timespan of 6 months. Started Mar 2019; status: terminated.
02
Drugs
collagenase clostridium histolyticum
03
Conditions
Esophageal stricture
Beyond the preview
Go deeper on NCT03898661.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03898661.